Zydus Lifesciences’ Verapamil Approval Analyzed
Zydus Lifesciences has just gotten the green light from the U.S. government to sell a new medicine called Verapamil Hydrochloride Extended-Release Tablets. This tablet helps people lower high blood pressure – which is a major cause of heart problems. This approval means more people can get access to a medicine that protects their hearts.
Key Points
- Zydus gained USFDA approval for Verapamil tablets, 120, 180, 240mg.
- Tablets reduce high blood pressure, protecting against heart issues.
- Production will occur in Baddi, Himachal Pradesh, India.
- Verapamil sales in the US totaled $24.5 million (Sept-2025).
- The medicine is for preventing strokes and heart attacks.
- This approval represents a strategic expansion of Zydus’ portfolio.
These tablets are designed to slowly release medicine into your body, keeping your blood pressure under control for a longer time. Zydus makes these tablets at their factory in Baddi, Himachal Pradesh, India.
According to IQVIA data, Verapamil tablets sold over $24.5 million in the United States during the period of September 2025. This shows that there’s a strong market interest in this type of medicine.
Access to effective blood pressure medication is critical for public health.
